Expertise in
7
conditions

Dr. Leona Holmberg

Oncology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Offers Telehealth
Expertise in
7
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Leona Holmberg is an Oncologist in Seattle, Washington. Dr. Holmberg is highly rated in 7 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Mantle Cell Lymphoma (MCL), Smoldering Multiple Myeloma, Hodgkin Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 106 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in WA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109
Other Locations
Fred Hutchinson Cancer Center
1100 Fairview Ave N, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma
Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 08, 2026
Intervention Type: Drug, Other
Study Drugs: Ixazomib Citrate, Lenalidomide
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 2
Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients After Initial Induction Therapy
Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients After Initial Induction Therapy
Enrollment Status: Withdrawn
Publish Date: February 01, 2021
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 2
A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF
A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF
Enrollment Status: Completed
Publish Date: July 12, 2017
Intervention Type: Radiation, Procedure, Drug, Biological
Study Phase: Phase 2
View 4 Less Clinical Trials

106 Total Publications

Impact of Post-Autologous Peripheral Blood Stem Cell Transplant (ASCT)- Granulocyte Colony Stimulating Factor (G-CSF) on Toxicity Profiles in Hodgkin Lymphoma (HL) Patients Receiving Pre-ASCT Immune Checkpoint Inhibitors (ICI).
Impact of Post-Autologous Peripheral Blood Stem Cell Transplant (ASCT)- Granulocyte Colony Stimulating Factor (G-CSF) on Toxicity Profiles in Hodgkin Lymphoma (HL) Patients Receiving Pre-ASCT Immune Checkpoint Inhibitors (ICI).
Journal: Transplantation and cellular therapy
Published: October 05, 2025
Similar Doctors
Expertise in
23
conditions
Dr. Ajay Gopal
Oncology
Expertise in
23
conditions
Dr. Ajay Gopal
Oncology

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ajay Gopal is an Oncologist in Seattle, Washington. Dr. Gopal is highly rated in 23 conditions, according to our data. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and B-Cell Lymphoma.

Expertise in
19
conditions
Dr. John Pagel
Oncology
Expertise in
19
conditions
Dr. John Pagel
Oncology

Swedish Cardiovascular RSRCH

1221 Madison St Ste 1020, 
Seattle, WA 
 (1.7 miles away)
206-215-2658
Languages Spoken:
English
See accepted insurances

John Pagel is an Oncologist in Seattle, Washington. Dr. Pagel is highly rated in 19 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Bart Scott
Oncology
Expertise in
13
conditions
Dr. Bart Scott
Oncology

Gme Office University Of Washington

1959 NE Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bart Scott is an Oncologist in Seattle, Washington. Dr. Scott is highly rated in 13 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Leukemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Leona Holmberg

How do I make an appointment with Dr. Leona Holmberg?

You can book an appointment with Dr. Leona Holmberg by calling their office at 206-288-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Leona Holmberg a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Leona Holmberg is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Leona Holmberg specialize in?

While Dr. Leona Holmberg is a Oncology, they have specific expertise in Multiple Myeloma, Mantle Cell Lymphoma (MCL), and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Leona Holmberg participate in research or clinical trials?

Yes. Dr. Leona Holmberg has published 106 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Leona Holmberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Leona Holmberg accept my insurance?

Dr. Leona Holmberg accepts most major insurance plans, including Humana and PacificSource. We recommend calling the office directly at 206-288-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Holmberg's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile